Inhibition of cell motility by troglitazone in human ovarian carcinoma cell line
2007

Troglitazone Reduces Cell Movement in Ovarian Cancer Cells

Sample size: 3 publication 10 minutes Evidence: moderate

Author Information

Author(s): Yang Yuh-Cheng, Ho Tsung-Chuan, Chen Show-Li, Lai Huei-Yi, Wu Ju-Yun, Tsao Yeou-Ping

Primary Institution: Mackay Medicine, Nursing and Management College, Taipei, Taiwan

Hypothesis

Does troglitazone inhibit cell migration in human ovarian carcinoma cells?

Conclusion

Troglitazone effectively suppresses the migration of ovarian cancer cells by affecting focal adhesion and PTEN activity.

Supporting Evidence

  • Troglitazone treatment reduced cell migration in a dose-dependent manner.
  • At 20 μM, troglitazone decreased cell migration by 76% after 24 hours.
  • Troglitazone inhibited the formation of focal adhesions and stress fibers.

Takeaway

Troglitazone is a medicine that can help stop cancer cells from moving around in the body, which is important for treating cancer.

Methodology

The study used wound-healing and transwell assays to evaluate cell migration after treating ES-2 ovarian carcinoma cells with troglitazone.

Participant Demographics

Human ovarian carcinoma cell line, ES-2.

Statistical Information

P-Value

<0.001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2407-7-216

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication